| Bioactivity | BChE-IN-14 (compound 19c) is a selective butyrylcholinesterase (BChE) inhibitor with IC50s of 0.23 and 0.011 μM for eqBChE and hBChE, respectively. BChE-IN-14 shows good blood brain barrier permeation and primary cell safety. BChE-IN-14 is able to restore cognitive impairment in vivo, it can be used for the research of Alzheimer’s disease[1]. |
| Target | IC50: 0.23 μM (eqBChE), 0.011 μM (hBChE) |
| Invitro | BChE-IN-14 (0.0001-100 μM) inhibits eqBChE from house serum and hBChE with IC50s of 0.23 and 0.011 μM, respectively[1]. |
| In Vivo | BChE-IN-14 (15 mg/kg; p.o. for Aβ1-42 injection days 3-8) affects memory and cognitive function in AD mice model[1]. Animal Model: |
| Name | BChE-IN-14 |
| CAS | 2700896-78-0 |
| Formula | C24H29N |
| Molar Mass | 331.49 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lu X, et al. Design, synthesis, and biological evaluation of aromatic tertiary amine derivatives as selective butyrylcholinesterase inhibitors for the treatment of Alzheimer's disease. Eur J Med Chem. 2022 Sep 2;243:114729. |
BChE-IN-14
CAS: 2700896-78-0 F: C24H29N W: 331.49
BChE-IN-14 (compound 19c) is a selective butyrylcholinesterase (BChE) inhibitor with IC50s of 0.23 and 0.011 μM for eqB
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.